We are live on ! Find out more
UPB icon

Upstream Bio

1.59 USD
-0.41
20.5%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
1.62
+0.03
1.89%
1 day
-20.5%
5 days
-43.62%
1 month
-43.62%
3 months
-76.79%
6 months
-81.09%
Year to date
-94.13%
1 year
-93.63%
5 years
-92.77%
10 years
-92.77%
 

About: Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).

Employees: 75

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 20%
Neutral 60%
Negative 20%
Negative
Zacks Investment Research
11 days ago
Upstream Bio, Inc. (UPB) Reports Q3 Loss, Lags Revenue Estimates
Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to a loss of $0.63 per share a year ago.
Upstream Bio, Inc. (UPB) Reports Q3 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
11 days ago
Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress
– Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 –
Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress
Positive
Market Watch
2 months ago
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
These beaten-down stocks could bounce back in January, if history is any guide
Neutral
GlobeNewsWire
2 months ago
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV 1 ) and exhaled nitric oxide (FeNO) with every 12-week dosing – – The Company remains on track to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027 , designed to deliver best-in-class efficacy in both indications by evaluating a 400 mg quarterly regimen of verekitug in broad patient populations – WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for severe inflammatory respiratory diseases, today presented results from the Phase 2 VALIANT clinical trial evaluating the safety and efficacy of verekitug in adults with severe asthma in a late-breaking oral presentation at the European Respiratory Society (ERS) Congress 2026 in Barcelona.
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
Neutral
GlobeNewsWire
2 months ago
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – – The Company's Phase 3 strategy is designed to deliver best-in-class efficacy across both indications by evaluating a high-dose, quarterly regimen of verekitug in broad patient populations – – The Company remains on track to initiate both Phase 3 trials in Q1 2027 – WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for severe inflammatory respiratory diseases, today announced its pivotal Phase 3 development plans for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
Negative
Zacks Investment Research
3 months ago
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.74 per share a year ago.
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Positive
Zacks Investment Research
4 months ago
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Neutral
GlobeNewsWire
5 months ago
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
Neutral
Business Wire
5 months ago
KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 65 classes of mortgage pass-through notes from OBX 2026-AHC2 Trust, a prime agency-eligible RMBS transaction sponsored by Onslow Bay Financial LLC, that is fully originated and serviced by AmeriHome Mortgage Company, LLC (AmeriHome). This transaction is comprised of 599 residential mortgages with an aggregate unpaid principal balance (UPB) of approximately $340.0 million as of the June 1, 2026 cut-off date. The underlying collateral.
KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust
Neutral
Seeking Alpha
5 months ago
Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Price charts implemented using Lightweight Charts™